Who is eligible for clinical trial NCT04592913?

Participants must meet protocol criteria for Gastrointestinal Neoplasms. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04592913 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-12-16

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer (NCT04592913)

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Who can join: Review the eligibility criteria below.

Location: Research Site — Duarte, California

Age range: 18 Years to 200 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (156 Sites)

Showing the first 25 of 156 sites.

Research Site — Duarte, California
Research Site — Los Angeles, California
Research Site — Los Angeles, California
Research Site — Sylmar, California
Research Site — St. Petersburg, Florida
Research Site — Tallahassee, Florida
Research Site — West Palm Beach, Florida
Research Site — Fort Wayne, Indiana
Research Site — Louisville, Kentucky
Research Site — Boston, Massachusetts
Research Site — New York, New York
Research Site — Rochester, New York
Research Site — Nashville, Tennessee
Research Site — Dallas, Texas
Research Site — Lancaster, Texas
Research Site — Seattle, Washington
Research Site — Buenos Aires,
Research Site — Ciudad Autonoma Buenos Aires,
Research Site — Ciudad de Buenos Aires,
Research Site — Ciudad de Buenos Aires,
Research Site — Rosario,
Research Site — Rosario,
Research Site — Charleroi,
Research Site — Edegem,
Research Site — Leuven,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Gastrointestinal Neoplasms

Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei — Houston, Texas
Monopolar Current Cutting Knife vs Bipolar RFA Knife — Houston, Texas
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors — Miami, Florida
Feasibility and Prospective Study of a Dynamic Traction Device for Use During ESD — Houston, Texas
The Canopy Cancer Collective Clinical Registry Protocol — San Diego, California

Explore by condition: All Gastrointestinal Neoplasms clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗